Investigating genetic variants in a protein linked to a common type of glaucoma
Official title: The Structural and Biochemical Effects of XFG-Associated Variants in LOXL1
Funded at Georgia Institute of Technology · NIH-10903489 · Data updated 2026-11-12
This study is looking at a protein linked to pseudoexfoliation glaucoma to see how different versions of it might affect the condition, which could help patients understand more about their eye health and vision loss.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $74,284 |
| NIH project number | 1F32EY036268-01 |
| Project ID | NIH-10903489 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pseudoexfoliation glaucoma or those with genetic variants linked to this condition.
✕Less likely to help
Patients without pseudoexfoliation glaucoma or those not carrying the associated genetic variants may not benefit from this research.
What this research studies
This research focuses on understanding the structural and biochemical properties of a protein called LOXL1, which is associated with pseudoexfoliation glaucoma (XFG). By examining both the normal and variant forms of LOXL1, the study aims to uncover how these genetic differences contribute to the development of XFG, a condition that can lead to vision loss. The research employs advanced techniques such as biomolecular nuclear magnetic resonance to analyze the protein's structure and function. Patients with XFG may benefit from insights gained about the underlying mechanisms of their condition.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and potential new treatments for patients suffering from pseudoexfoliation glaucoma.
How similar studies have gone: Previous research has shown promising results in understanding genetic factors in glaucoma, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Georgia Institute of Technology
Atlanta, United States Active
Researchers
- Principal investigator: Youngblood, Hannah Abigail — Georgia Institute of Technology
- Study coordinator: Youngblood, Hannah Abigail
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.